Swiss biopharma NLS Pharmaceutics reports promising preclinical results for potential Parkinson's disease treatments using its non-sulfonamide dual orexin agonist platform.
Swiss biopharma NLS Pharmaceutics reports promising preclinical results for potential Parkinson's disease treatments. The company used its non-sulfonamide dual orexin agonist (DOXA) platform to develop multiple compounds, showing positive effects on neurite outgrowth in vitro studies. These results suggest potential differentiated and more effective treatments for Parkinson's Disease patients, targeting alpha-synuclein (specifically the A53T mutation). Further research is needed to elucidate precise mechanisms and long-term efficacy and safety.
June 27, 2024
6 Articles